Name | Type | Posted | Actions |
|---|---|---|---|
Tech-Snapshot-DCRecruiter-26-24915.pdf | Jun 15, 2026 |
TECHNOLOGY LICENSING OPPORTUNITY: DC Recruiter
Contact and place of performance
Caleb Ledgerwood
Los Alamos, NM 87545
USA
DC Recruiter: Broad-Spectrum Immune Enhancer from scientists at Los Alamos National Laboratory offers a differentiated approach to multi-pathogen infection prevention by using a self-assembling peptide nanofiber to recruit and activate dendritic cells (DCs), the immune system’s natural sentinels. Unlike pathogen-specific vaccines or therapeutics, it is designed to help trigger an early immune response regardles...
View moreProblems Solved:
DC Recruiter solves this problem by using a specific peptide selected to bind to dendritic cells. By leveraging a self-assembling peptide nanofiber platform, the technology is designed to help “wake up” immune surveillance early, before infection can progress unchecked. Rather than relying on a treatment matched to one virus or bacterium, it creates the potential for broad-spectrum immune support across many different infectious threats. Its ability to provide broad-spectrum immune support makes it especially compelling for situations where time is critical and conventional options may be too specific, too slow or too late to provide immediate protection. The needle-free, spray-friendly concept also adds practical value by supporting easier administration and broader accessibility, strengthening its fit for real-world use cases that demand rapid, flexible deployment.
Key Advantages:
Market Applications:
Development Status: TRL 3
US Patent pending
LA-UR-26-24915
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
m.lanl.gov/tech-search
The Department of Energy, through its contractor Triad at Los Alamos National Laboratory, is offering a technology licensing opportunity for DC Recruiter, a broad-spectrum immune enhancer. This technology uses a self-assembling peptide nanofiber platform to recruit and activate dendritic cells, triggering an early immune response regardless of the specific infecting agent. The opportunity is identified by solicitation number S-195061 and falls under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) and PSC AJ13 GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT. There is no set-aside (NONE) assigned to this notice.
DC Recruiter addresses gaps in infection management by providing a rapid, pathogen-agnostic method to stimulate immune defenses before a specific threat is identified. The technology is designed as a needle-free, spray-friendly application for use in outbreak situations, field environments, and high-risk settings. It is currently at technology readiness level (TRL) 3 with a U.S. patent pending under identifier LA-UR-26-24915. Potential market applications include infectious disease prevention, national security biological threat preparedness, and emergency response.
The response deadline for this special notice is December 16, 2026, and the place of performance is Los Alamos, New Mexico. Caleb Ledgerwood is the designated point of contact. Supporting documentation is available in one PDF attachment titled Tech-Snapshot-DCRecruiter-26-24915.pdf. The laboratory facilitates the transition of such inventions into commercial innovations through both exclusive and non-exclusive licensing agreements.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.